Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data
Authors' conclusion
- The high number of treatment prescriptions in a short period highlights the high unmet medical need. No new safety concerns were identified in this population with severe obesity treated in a real-world setting.
Study context
- Population
- French patients with body mass index (BMI) ≥40 kg/m² and ≥1 treated weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, CVD) receiving semaglutide 2.4 mg; age 18 to 81 years
- Participants
- 478 vs 8,568
- Exposure
- TUA vs EAP
- TUAn = 478
- EAPn = 8,568
- Outcome
- Baseline BMI
- Follow-up
- Baseline
Methodological detailsTemporary Utilization Authorization and Early Access Program cohorts, descriptive statistics only
- Temporary Utilization Authorization and Early Access Program cohorts
- Descriptive statistics only
Main finding
As reported in the abstract
- Treatment requests sent by sites specialized in obesity management
- 5,797 (62.8%)
Observational data: associations, not effects.
Further findings
Number of WRC (EAP) · baseline
- 1 WRC
- 57.4%
- 2 WRC
- 26.5%
- 3 WRC
- 12.3%
- 4 WRC
- 3.7%
Other comorbidities · baseline
- T2D
- 15.5%
- Depression
- 18.1%
- Osteoarthritis
- 15.4%
Safety
| Outcome | TUA | EAP |
|---|---|---|
| Treatment discontinuationTUA count: discontinued due to AEs | 3 events | 2.9% |
| Median time to discontinuation | — not stated in the abstract | 2.8 months (IQR: 1.2-5.1) |
| Due to AEs | — not stated in the abstract | 47.0% |
— not stated in the abstract
Pancreatitis
- Pancreatitis cases overall
- 7
Original publication
Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data. Diabetes Metab. Published 17 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →